[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1123824T1 - Προερχομενα απο βακτηρια, ακεραια μινικυτταρα για μεταφορα θεραπευτικων παραγοντων σε ογκους εγκεφαλου - Google Patents

Προερχομενα απο βακτηρια, ακεραια μινικυτταρα για μεταφορα θεραπευτικων παραγοντων σε ογκους εγκεφαλου

Info

Publication number
CY1123824T1
CY1123824T1 CY20201101075T CY201101075T CY1123824T1 CY 1123824 T1 CY1123824 T1 CY 1123824T1 CY 20201101075 T CY20201101075 T CY 20201101075T CY 201101075 T CY201101075 T CY 201101075T CY 1123824 T1 CY1123824 T1 CY 1123824T1
Authority
CY
Cyprus
Prior art keywords
brain tumors
bacteria
delivery
therapeutic agents
brain
Prior art date
Application number
CY20201101075T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd. filed Critical Engeneic Molecular Delivery Pty Ltd.
Publication of CY1123824T1 publication Critical patent/CY1123824T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η συστηματική χορήγηση ακέραιων, προερχόμενων από βακτήρια μινικυττάρων οδηγεί σε ταχεία συσσώρευση των μινικυττάρων στο μικροπεριβάλλον ενός όγκου του εγκεφάλου, σε θεραπευτικώς σημαντικές συγκεντρώσεις, χωρίς να απαιτείται ενδοθηλιακή ενδοκυττάρωση/διακυττάρωση μέσα από τον αιματοεγκεφαλικό φραγμό ή κάποιος άλλος μηχανισμός με τον οποίο, σύμφωνα με συμβατικές προσεγγίσεις, έχουν εισαχθεί νανοσωματίδια σε αυτό το μικροπεριβάλλον. Έτσι, μια μεγάλη ποικιλία όγκων του εγκεφάλου, τόσο πρωτογενών όσο και μεταστατικών, μπορούν να αντιμετωπιστούν με συστηματική χορήγηση μιας θεραπευτικώς αποτελεσματικής ποσότητα μιας σύνθεσης που αποτελείται από ένα πλήθος τέτοιων μινικυττάρων, όπου κάθε τέτοιο μινικύτταρο είναι ένα όχημα για έναν δραστικό παράγοντα έναντι του όγκου, όπως ένα ραδιονουκλίδιο, ένα λειτουργικό νουκλεϊνικό οξύ ή ένα πλασμίδιο που το κωδικοποιεί, ή ένας χημειοθεραπευτικός παράγοντας.
CY20201101075T 2011-12-13 2020-11-13 Προερχομενα απο βακτηρια, ακεραια μινικυτταρα για μεταφορα θεραπευτικων παραγοντων σε ογκους εγκεφαλου CY1123824T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569907P 2011-12-13 2011-12-13
PCT/IB2012/002950 WO2013088250A1 (en) 2011-12-13 2012-12-12 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

Publications (1)

Publication Number Publication Date
CY1123824T1 true CY1123824T1 (el) 2022-03-24

Family

ID=48611925

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101075T CY1123824T1 (el) 2011-12-13 2020-11-13 Προερχομενα απο βακτηρια, ακεραια μινικυτταρα για μεταφορα θεραπευτικων παραγοντων σε ογκους εγκεφαλου

Country Status (24)

Country Link
US (3) US9844598B2 (el)
EP (1) EP2790668B1 (el)
JP (2) JP6522340B2 (el)
KR (2) KR20140102294A (el)
CN (2) CN104114153A (el)
AU (2) AU2012351743B2 (el)
CA (1) CA2858315C (el)
CY (1) CY1123824T1 (el)
DK (1) DK2790668T3 (el)
ES (1) ES2843402T3 (el)
HK (1) HK1201473A1 (el)
HR (1) HRP20201930T1 (el)
HU (1) HUE052136T2 (el)
IL (1) IL233031B (el)
LT (1) LT2790668T (el)
MX (1) MX359410B (el)
PT (1) PT2790668T (el)
RS (1) RS61161B1 (el)
RU (1) RU2664698C2 (el)
SG (2) SG11201403062YA (el)
SI (1) SI2790668T1 (el)
SM (1) SMT202000676T1 (el)
TW (1) TWI627966B (el)
WO (1) WO2013088250A1 (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516056C (en) * 2003-01-06 2012-05-29 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
TR201905480T4 (tr) 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (el) 2009-07-02 2015-05-01 Angiochem Inc
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102014061B1 (ko) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
DK2790668T3 (da) 2011-12-13 2020-11-23 Engeneic Molecular Delivery Pty Ltd Bakterielt afledte, intakte miniceller til levering af terapeutiske midler til hjernetumorer
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SG11201602429QA (en) * 2013-10-04 2016-04-28 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
CN114099686B (zh) * 2014-07-15 2024-04-16 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
WO2017112943A1 (en) 2015-12-23 2017-06-29 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
DE102018220892A1 (de) * 2018-12-04 2020-06-04 Robert Bosch Gmbh Vorrichtung und Verfahren zur Generierung von Labelobjekten für die Umgebung eines Fahrzeugs
EP3893856A4 (en) * 2018-12-10 2022-10-05 Flagship Pioneering Innovations VI, LLC ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMS
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
CN114641310A (zh) * 2019-06-21 2022-06-17 德克萨斯大学系统董事会 治疗癌症和其他疾病的靶向α3β1整合素
CN111001014B (zh) * 2019-12-12 2022-04-22 四川大学华西医院 一种基于固定细菌做载体的抗肿瘤药物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0222340Y2 (el) 1986-11-18 1990-06-15
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2000059547A2 (en) 1999-04-02 2000-10-12 Center For Molecular Medicine And Immunology Method of detecting endometriosis
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030203411A1 (en) * 2001-06-05 2003-10-30 Sabbadini Roger A. Methods of minicell-based delivery
AU2002347426B2 (en) * 2001-10-15 2007-05-10 Engeneic Molecular Delivery Pty Ltd Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20040005700A1 (en) 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
EP1507562B1 (en) 2002-05-29 2010-03-24 Immunomedics, Inc. Compositions for radioimmunotherapy of brain
EP1546203B1 (en) * 2002-08-01 2012-06-20 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
PT1694361E (pt) 2003-12-09 2011-06-27 Engeneic Molecular Delivery Pty Ltd Transporte direccionado de genes a células de mamífero não fagocíticas por meio de minicélulas intactas derivadas de bactéria
SG169373A1 (en) 2004-02-02 2011-03-30 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US7837998B2 (en) * 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
DK2386640T3 (en) * 2004-08-26 2015-04-27 Engeneic Molecular Delivery Pty Ltd The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells
JP2008533157A (ja) 2005-03-14 2008-08-21 マサチューセッツ・インスティテュート・オブ・テクノロジー 疾患および障害の診断および処置のためのナノセル
JP2009531324A (ja) * 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
CN101505768B (zh) * 2006-06-23 2013-11-06 因詹尼克分子递送控股有限公司 通过完整的死亡细菌细胞将药物、治疗性核酸和功能性核酸靶向递送至哺乳动物细胞
EP2076292A2 (en) 2006-10-25 2009-07-08 Koninklijke Philips Electronics N.V. Contrast agents for detecting prostate cancer
DK2145002T3 (en) 2007-03-30 2015-04-20 Engeneic Molecular Delivery Pty Ltd Bacterially-derived, intact minicells comprising the plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
ES2569909T3 (es) * 2008-06-25 2016-05-13 Vaxiion Therapeutics, Llc Composiciones y métodos del mecanismo de suicidio genético regulado
EP2376534A4 (en) * 2008-12-05 2012-05-30 Abraxis Bioscience Llc SPARC-BINDING ScFc
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
JP6199746B2 (ja) * 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
DK2790668T3 (da) * 2011-12-13 2020-11-23 Engeneic Molecular Delivery Pty Ltd Bakterielt afledte, intakte miniceller til levering af terapeutiske midler til hjernetumorer
CA3107095A1 (en) 2018-07-23 2020-01-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same

Also Published As

Publication number Publication date
EP2790668B1 (en) 2020-09-09
CN109125286A (zh) 2019-01-04
JP2015500328A (ja) 2015-01-05
US20180043027A1 (en) 2018-02-15
ES2843402T3 (es) 2021-07-16
CA2858315A1 (en) 2013-06-20
IL233031B (en) 2019-12-31
HK1201473A1 (en) 2015-09-04
US20130177499A1 (en) 2013-07-11
TW201330860A (zh) 2013-08-01
NZ709680A (en) 2017-03-31
SMT202000676T1 (it) 2021-01-05
DK2790668T3 (da) 2020-11-23
AU2017239542A1 (en) 2017-10-26
JP6522340B2 (ja) 2019-05-29
KR102046042B1 (ko) 2019-11-18
RU2664698C2 (ru) 2018-08-21
JP6594383B2 (ja) 2019-10-23
WO2013088250A4 (en) 2013-10-24
TWI627966B (zh) 2018-07-01
NZ626187A (en) 2016-06-24
RU2014128338A (ru) 2016-02-10
HRP20201930T1 (hr) 2021-02-05
US20210213133A1 (en) 2021-07-15
US9844598B2 (en) 2017-12-19
EP2790668A4 (en) 2015-07-15
KR20140102294A (ko) 2014-08-21
US10994014B2 (en) 2021-05-04
WO2013088250A1 (en) 2013-06-20
JP2018024678A (ja) 2018-02-15
SG11201403062YA (en) 2014-07-30
AU2017239542B2 (en) 2019-04-04
PT2790668T (pt) 2020-11-10
SI2790668T1 (sl) 2021-01-29
IL233031A0 (en) 2014-07-31
RS61161B1 (sr) 2021-01-29
AU2012351743A1 (en) 2014-07-03
CN104114153A (zh) 2014-10-22
AU2012351743B2 (en) 2017-07-06
EP2790668A1 (en) 2014-10-22
CA2858315C (en) 2020-05-12
SG10201601349XA (en) 2016-03-30
US11964021B2 (en) 2024-04-23
MX359410B (es) 2018-09-27
LT2790668T (lt) 2020-12-28
KR20190084349A (ko) 2019-07-16
MX2014006967A (es) 2014-12-05
HUE052136T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
CY1123824T1 (el) Προερχομενα απο βακτηρια, ακεραια μινικυτταρα για μεταφορα θεραπευτικων παραγοντων σε ογκους εγκεφαλου
BR112014010383A2 (pt) proteína de ligação a antígeno e uso do mesmo como produto direcionado a alvo para o tratamento de câncer
CY1123684T1 (el) Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι
JP2018513104A5 (el)
CY1125263T1 (el) Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa
CY1120560T1 (el) Βελτιστοποιημενο συστημα παραδοσης in vivo me ενδοσωματολυτικους παραγοντες για συζευγματα νουκλεϊνικου οξεος
NZ753018A (en) Conjugated antisense compounds and their use
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1119744T1 (el) Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
CY1120039T1 (el) Ογκολυτικοι αδενοϊικοι φορεις και μεθοδοι και χρησεις οι οποιες σχετιζονται με αυτους
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
Bonnet et al. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition
ZA201706745B (en) Site-specific antibody-drug conjugates
MX2015016588A (es) Estructura, fabricacion y usos de los peptidos permeables a las celulas, derivados de humanos, conjugados con los peptidos de carga especificos, biologicamente activos.
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX354618B (es) Sistema de nanopartículas nts-poliplex para terapia génica de cáncer.
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
WO2016164743A3 (en) Cd38 ligand-drug conjugates for targeted cancer therapy
WO2013119371A3 (en) Mini-intronic plasmid vectors
EP3877002A4 (en) Hybrid immolative cell-penetrating complexes for nucleic acid delivery
CY1119430T1 (el) Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου
BR112014016723A2 (pt) método para o tratamento de câncer de mama